New radioactive treatment for advanced kidney cancer after other drugs stop working

Plain-English translation of NCT06783348 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new treatment called 177Lutetium-PSMA-617, which is a radioactive medication designed to target and attack cancer cells. The trial is for people with advanced kidney cancer (a type called clear cell renal carcinoma) whose cancer has continued to grow even after receiving two standard treatment approaches. This medication has shown promise in treating a different type of cancer (prostate cancer), and researchers believe it might help kidney cancer patients too.

After patients receive standard kidney cancer treatments (immunotherapy drugs and targeted therapy drugs), there are limited options if the cancer continues to grow. This medication offers a new approach that has shown good results with manageable side effects in other cancers, so researchers want to test whether it can help kidney cancer patients at this later stage of their disease.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced kidney cancer (clear cell renal carcinoma) that has spread to other parts of your body
your cancer has grown or worsened despite receiving at least two standard treatments (an immunotherapy drug and a targeted therapy drug)
you are at least 18 years old and in generally good health
a special imaging scan shows that your cancer cells have the marker (PSMA) that this medication targets
your blood work and organ function are adequate to safely receive the treatment

You likely don't qualify if…

you are pregnant or breastfeeding, or unwilling to use effective birth control during and for 14 weeks after treatment
your blood cell counts or kidney and liver function are too low
your cancer has PSMA-negative lesions (spots that the medication cannot target) or you have only non-measurable disease
you have an Eastern Cooperative Oncology Group performance status of 2 or higher (meaning you are significantly limited in your daily activities)

What participation looks like

If you qualify, you will receive the radioactive medication through an intravenous infusion (IV) every 6 weeks, with the first dose within 3 weeks of joining the trial. You will receive up to 4 initial doses, and if your cancer shrinks or stays stable, you may receive 2 additional doses for a total of up to 6 treatments. Throughout the trial, you will have regular blood tests, imaging scans, and clinic visits to monitor how the medication is working and check for side effects.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(2 sites)

France

Centre Francois Baclesse (CLCC), Caen

Gustave Roussy, Villejuif

Key details

Phase

Testing effectiveness

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators

Advanced Accelerator Applications

Enrollment target

~48 participants

Started

April 2026

Primary completion

January 2028

Age range

18 Years – 100 Years

Last updated on clinicaltrials.gov in June 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

EORTC

Cliniques Universitaires de Saint Luc

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov